吉貝爾(688566.SH):暫未接入AI平臺
格隆匯2月18日丨吉貝爾(688566.SH)在投資者互動平臺表示,按照公司2024年年度報告編制及披露計劃,公司2024年年度報告將於2025年4月15日披露。公司將按照相關規定在2025年2月底前披露2024年度業績快報,敬請關注。 按照公司目前的計劃,抗抑鬱新藥JJH201501 Ⅲ期臨牀試驗將在2025年3月底前完成受試者入組工作,入組完成後開展隨訪觀察、數據整理等,2025年底前完成Ⅲ期臨牀研究和新藥上市申請,敬請關注。 隨着人工智能(AI)技術的持續發展,將人工智能(AI)技術應用於新藥研發領域正成爲醫藥行業的前沿趨勢,公司暫未接入AI平臺,將對相關技術在醫藥領域的發展與應用保持積極關注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.